PEMBROLIZUMAB IN THE TREATMENT OF METASTATIC MELANOMA

PEMBROLIZUMAB IN THE TREATMENT OF METASTATIC MELANOMA

Currently in Russia drugs a new class - immunological synapse modulators (ISM) – appear, the most effective among which are PD-1 blockers. Pembrolizumab is an effective antineoplastic drug, which is a monoclonal antibody blocking the PD-1 signaling molecule on cytotoxic lymphocytes, inhibiting the i...

Bibliografiset tiedot
Päätekijät:	I. V. SAMOILENKO, L. V. DEMIDOV
Aineistotyyppi:	Artikkeli
Kieli:	Russian
Julkaistu:	Remedium Group LLC 2017-06-01
Sarja:	Медицинский совет
Aiheet:	metastatic melanoma immunology pembrolizumab pd-1 blockers
Linkit:	https://www.med-sovet.pro/jour/article/view/1882

Samankaltaisia teoksia

Limbic encephalitis in metastatic malignant melanoma patient induced by PD-1 checkpoint inhibitor pembrolizumab
Tekijä: Rozala Arko, et al.
Julkaistu: (2022-07-01)

AIHA and Pancytopenia as Complications of Pembrolizumab Therapy for Metastatic Melanoma: A Case Report
Tekijä: Dan Ni, et al.
Julkaistu: (2019-06-01)

Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab – real-world experience
Tekijä: Hribernik Nezka, et al.
Julkaistu: (2020-01-01)

A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
Tekijä: Wu L, et al.
Julkaistu: (2021-02-01)

Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease
Tekijä: Xiang Dan, et al.
Julkaistu: (2024-04-01)

Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
Tekijä: Neta Tsur, et al.
Julkaistu: (2019-10-01)

Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study
Tekijä: Lu Si, et al.
Julkaistu: (2022-10-01)

Metastatic porocarcinoma: A case demonstrating objective response to pembrolizumab
Tekijä: Camélia Benhayoun, et al.
Julkaistu: (2024-08-01)

MODERN TREATMENT OF METASTATIC MELANOMA: FROM STANDARDS TO AN INDIVIDUALIZED APPROACH IN REAL CLINICAL PRACTICE
Tekijä: N. V. Zhukova, et al.
Julkaistu: (2018-06-01)

Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma – A case report
Tekijä: R. Kuint, et al.
Julkaistu: (2017-01-01)

Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers
Tekijä: Vishal Navani, et al.
Julkaistu: (2021-08-01)

Complete response in a patient with BRAF-mutant metastatic melanoma achieved with the multidisciplinary approach: a case report
Tekijä: Hana Garaj, et al.
Julkaistu: (2024-01-01)

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma
Tekijä: Ester Simeone, et al.
Julkaistu: (2017-03-01)

Metastatic melanoma with features of blue nevus and tumoral melanosis identified during pembrolizumab therapy
Tekijä: Matthew F. Helm, MD, et al.
Julkaistu: (2017-03-01)

Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis
Tekijä: Zhang Qi, et al.
Julkaistu: (2020-06-01)

IPILIMUMAB IN THERAPY OF METASTATIC MELANOMA
Tekijä: I. V. SAMOILENKO, et al.
Julkaistu: (2016-12-01)

Case report: Bilateral uveitis and papillitis secondary to treatment with pembrolizumab
Tekijä: Carmen Navarro-Perea, et al.
Julkaistu: (2019-01-01)

Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
Tekijä: Ronen Stoff, et al.
Julkaistu: (2023-05-01)

Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study
Tekijä: Henrik Jespersen, et al.
Julkaistu: (2019-05-01)

Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone
Tekijä: Samuel Rosner, et al.
Julkaistu: (2017-04-01)

Atypical Stevens–Johnson syndrome caused by pembrolizumab in the treatment of metastatic melanoma – Are corticosteroids a safe treatment option?
Tekijä: Cathal O'Connor, et al.
Julkaistu: (2020-01-01)

Immunotherapy after progression to double immunotherapy: pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
Tekijä: Georgios Lyrarakis, et al.
Julkaistu: (2024-10-01)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
Tekijä: Inokuchi J, et al.
Julkaistu: (2019-05-01)

Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland
Tekijä: Arjun Bhadhuri, et al.
Julkaistu: (2019-12-01)

Challenging the standard of care in advanced melanoma: focus on pembrolizumab
Tekijä: Abdul-Karim RM, et al.
Julkaistu: (2017-09-01)

Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma
Tekijä: Yuan Yao, et al.
Julkaistu: (2025-02-01)

Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report
Tekijä: Sivraj Muralikrishnan, et al.
Julkaistu: (2020-01-01)

A case of acute lymphocytic gastritis related to treatment with pembrolizumab for metastatic urothelial carcinoma
Tekijä: Yousuke Fukiishi, et al.
Julkaistu: (2023-03-01)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
Tekijä: Nobutaka Nishimura, et al.
Julkaistu: (2022-09-01)

Monitoring Patient Response to Pembrolizumab With Peripheral Blood Exhaustion Marker Profiles
Tekijä: Moira Graves, et al.
Julkaistu: (2019-05-01)

PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma
Tekijä: Sagun Parakh, et al.
Julkaistu: (2021-06-01)

Response of Metastatic Chordoma to the Immune Checkpoint Inhibitor Pembrolizumab: A Case Report
Tekijä: Xiaoli Wu, et al.
Julkaistu: (2020-12-01)

Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome
Tekijä: Sim Vermeulen, et al.
Julkaistu: (2021-04-01)

Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis
Tekijä: Alessio Cirillo, et al.
Julkaistu: (2024-04-01)

A real-world study on the safety profile of extended-interval dosing of immune checkpoint inhibitors for melanoma: a single-center analysis in Japan
Tekijä: Takamichi Ito, et al.
Julkaistu: (2023-12-01)

A Rare Case Report of Metastatic Urothelial Carcinoma to Skull with Significant Reossification after Pembrolizumab
Tekijä: Yung-Hao Liu, et al.
Julkaistu: (2021-09-01)

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
Tekijä: Pingyu Chen, et al.
Julkaistu: (2022-08-01)

Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer
Tekijä: Jing Nie, et al.
Julkaistu: (2024-01-01)

Real-world experience with pembrolizumab toxicities in advanced melanoma patients: a single-center experience in the UK
Tekijä: Alfred CP So, et al.
Julkaistu: (2018-03-01)

Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma
Tekijä: Tanja Batinac, et al.
Julkaistu: (2022-02-01)